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peridone. Methods: Cost-utility analysis was performed using a Markov model. 
The primary outcome was ICER/QALY. Oral risperidone, oral paliperidone and 
long-acting risperidone were selected as comparators. The basic components of 
the model include probabilities of relapse, individual hazard ratios for non-com-
pliance by medication type and switch of treatment probabilities. Specific utili-
ties for each health state were considered. Among relevant costs, reflecting payer’s 
perspective, drug acquisition costs, monitoring costs, costs of relapses, follow-up 
care and adverse events were considered. Results: Long-acting paliperidone 
reached ICER of EUR 16,233/QALY compared to oral risperidone, EUR 15,058/QALY 
to oral paliperidone and EUR 335/QALY to long-acting risperidone. The robustness 
of the model was supported by one-way deterministic analysis and probabilistic 
sensitivity analysis, which gave stable results. Long-acting paliperidone was cost 
effective in 97% of the simulations compared to oral risperidone. Long-acting pali-
peridone treatment gained incremental 0.903 QALYs on average compared to oral 
risperidone. ConClusions: The treatment of schizophrenia using long-acting 
paliperidone is associated with increased QALYs. It reduces incidence of adverse 
events, results in better prevention of relapses and can be considered a cost-effective 
treatment in the Czech Republic.
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objeCtives: Switching to vortioxetine (a new antidepressant) after inadequate 
response to selective serotonin re-uptake inhibitor/serotonin–norepinephrine 
reuptake inhibitor (SSRI/SNRI) resulted in a significant and clinically relevant 
improvement versus agomelatine (REVIVE head-to-head clinical study) and also 
better efficacy over sertraline, venlafaxine and bupropion (indirect comparison). 
The aim of this study is to assess the Finnish cost-utility of vortioxetine versus 
these antidepressants in patients who switch due to inadequate response to 
previous treatments. Methods: A one year cost-utility analysis was performed 
using a decision tree model for the second line and a Markov model for subse-
quent lines of MDD treatment. Undiscounted payer and societal perspectives were 
considered. Three health-states (depression, remission, recovery) and two treat-
ment phases (2-month acute, 6-month maintenance) were defined. The relative 
efficacy of antidepressants was derived from the REVIVE trial and indirect com-
parisons at 2 months. Efficacy in subsequent treatment steps was derived from the 
STAR*D study. Adverse events and their consequences were included and derived 
from REVIVE, indirect comparisons, literature and expert opinion. Utilities were 
derived from REVIVE and the literature using Finnish preference weights. Finnish 
costs in 2013/2014 value were considered. Sensitivity analyses were conducted to 
assess the robustness of the findings. Results: Vortioxetine was dominant from 
the payer’s and societal perspective versus all comparators. It was projected to 
result to QALY gain of 0.013, 0.017, 0.025 and 0.028, and € 223 (€ 1074), € 128 (€ 957), € 110 
(€ 720) and € 238 (€ 1390) direct (total) annual cost saving compared to agomelatine, 
bupropion, venlafaxine and sertraline respectively. These results were confirmed to 
be robust in several sensitivity analyses. ConClusions: Vortioxetine dominated 
agomelatine, bupropion, venlafaxine and sertraline in Finland and appears to be a 
relevant treatment option for MDD patients who need a therapy switch.
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objeCtives: To estimate the cost-effectiveness of paliperidone palmitate (PLAI), 
a once-monthly long-acting injectable (LAI) atypical antipsychotic, compared 
to the most common antipsychotic strategies in France. Methods: A Markov 
model was developed to simulate the progression of a cohort of schizophrenic 
patients through four health states (stable treated, stable non-treated, relapse 
and death) and up to three lines of treatment. PLAI was compared to risperidone 
LAI (RLAI), aripiprazole LAI (ALAI), olanzapine LAI (OLAI), haloperidol decanoate 
(HLAI) and oral olanzapine (OO). Costs, quality-adjusted-life-years (QALYS) and 
number of relapses were assessed over five years based on three-month cycles, 
and discounted at 4%, from a health insurance perspective. Patients were sup-
posed to be stabilised after a clinical decompensation and entered the model into 
an initiation phase, followed by a relapse prevention phase in case of success. 
In the prevention phase, relapse rates were derived from hospitalisation risks 
based on French real-life data in order to capture the adherence effects. Safety 
and utility data were derived from international publications. Costs came from 
French health insurance databases and publications. Robustness of results was 
assessed through deterministic and probabilistic sensitivity analyses. Results: 
PLAI was the less costly LAI and associated with an incremental cost-effectiveness 
ratio (ICER) of € 1,988/QALY gained and € 2,267/relapse avoided versus OO. RLAI 
and PLAI were associated with the highest number of QALYs (ICER of € 2,421,386/
QALY gained between PLAI and RLAI). PLAI dominated all other LAIs in terms of 
relapse but OLAI. Nevertheless, PLAI was highly cost-effective versus OLAI (ICER of 
€ 1,575,217/relapse avoided). ConClusions: This analysis is the first to assess the 
cost-effectiveness of antipsychotics based on French observational data. PLAI was 
found to be the least expensive LAI antipsychotic from French payer perspective. 
Oral therapies were less expensive but associated with lower levels of QALYs and 
more relapses compared to all atypical LAIs.
£6000 for all scenarios and a 100% probability of being cost-effective at a willingness 
to pay of £20,000 per QALY. Verbal therapy appeared more cost-effective than art 
therapy with a cost per QALY below £1000 but there was considerable uncertainty 
in the decision and a sizeable probability (20%) that art therapy was dominant. 
In neither comparison was the art therapy intervention similar to that employed 
in England and Wales, furthermore in the wait list comparison patients were not 
explicitly diagnosed with non-psychotic mental disorders. As such, the generalis-
ability of the results to practice in England and Wales is uncertain. ConClusions: 
Art therapy appears cost effective versus wait-list but of uncertain value compared 
with verbal therapy. Confirmatory studies are required to allow more definitive 
statements to be made.
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Cost-effeCtiVeness of litHiUM VersUs an atyPiCal anti-PsyCHotiC 
(aaP) UseD to aUgMent treatMent witH a seleCtiVe serotonin 
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objeCtives: To estimate the cost-effectiveness of augmentation of SSRI antidepres-
sant therapy with either lithium or an AAP in TRD, defined as failure to respond to 
two or more antidepressants. Methods: CENTRAL, EMBASE, MEDLINE, PsycINFO 
and NHS Economic Evaluation Database (NHS EED) were searched from inception 
to August 2011. Additional data were obtained from manufacturers. Systematic 
reviews of the economic and quality of life (QoL) literature were executed. Studies 
were assessed, independently by two reviewers, for quality against predefined cri-
teria. A de novo probabilistic economic model was developed to synthesise the 
available data on costs and clinical effectiveness from UK NHS perspective; time 
horizon 1-year (8 weeks of acute treatment and 10 months of maintenance treat-
ment). Results: Four economic evaluations (none directly addressing the review 
question) and 17 QoL studies were identified and summarised in narrative reviews. 
Model results indicate that augmentation of an SSRI with lithium dominates aug-
mentation with AAP (i.e. Results in cost savings of £905 per person per year and 
generates more health benefits, estimated to be 0.03 quality-adjusted life-years). 
However, sensitivity analyses showed that the model was highly sensitive to 
changes in acute treatment efficacy (response and remission) or discontinuation. 
The model was not sensitive to changes in other parameters. ConClusions: Cost-
effectiveness analyses suggest that augmentation with lithium is less expensive 
and more effective than augmentation with AAP. However, the uncertainty in the 
clinical estimates of discontinuation and treatment response is reflected in the 
model results. An RCT comparing the two augmentation strategies, reporting rel-
evant outcomes, including QoL, is needed.
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objeCtives: Computerised cognitive behaviour therapy (cCBT) forms a core com-
ponent of stepped psychological care within primary care in the UK and other 
countries. However, the existing clinical effectiveness evidence for cCBT comes 
from developer-led trials and independent research is needed which evaluates the 
clinical and cost-effectiveness of cCBT. Methods: A cost-effectiveness analysis 
was undertaken comparing two cCBT software packages, free-to-use MoodGYM 
and a commercial pay-to-use Beating the Blues (BtB), in addition to usual 
general practitioner care (UGPC), with UGPC alone, for the treatment of depressed 
adults. The analysis was based on data collected on the Randomised Evaluation of 
the Effectiveness and Acceptability of Computerised Therapy (REEACT). REEACT 
was a large (n= 691), pragmatic multicentre study, independently conducted in 
a primary care setting. Outcomes were assessed using EQ-5D and used to esti-
mate quality-adjusted life-years (QALYs). Resource use and costs were esti-
mated from a NHS and Personal Social Services perspective. Scenario analyses 
were performed to determine the impact on cost-effectiveness of alterna-
tive assumptions, and uncertainty was characterised using cost-effectiveness 
acceptability curves. Results: BtB was both more expensive and generated lower 
QALYs than UGPC alone (dominated) and MoodGYM yielded lower QALYs but at 
lower cost, resulting in an ICER of £6,933 per additional QALY for UGPC alone 
versus MoodGYM. UGPC alone was the most cost-effective intervention in the 
majority of scenario analyses, and the intervention most likely to be cost-effec-
tive at a £20,000 per QALY threshold (probabilities ranging across scenarios from 
0.545 to 0.619). ConClusions: Our findings indicate that commercially-produced 
products were no more effective than free-to-use cCBT programmes. Importantly, 
neither BtB or MoodGYM appeared cost-effective compared to UGPC alone. Practice 
recommendations such as those offered by NICE and other countries supporting 
the use of cCBT within stepped models of care for depression will need to be 
reconsidered in light of these results.
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objeCtives: The number of patients with schizofrenia in the Czech Republic 
amounts annually to approximately 126,000. Schizophrenia causes signifi-
cant increases in mortality, shortening life expectancy by 25 years compared to 
the general population which implies high disease burden. The aim was to esti-
mate the cost-effectiveness of long-acting paliperidone in the treatment with 
schizofrenia compared to oral risperidone, oral paliperidone and long-acting ris-
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in terms of longer length of stay, more readmissions and higher consumption of 
drugs. The average quality of the studies was moderate. Further research is needed 
to establish the degree of burden of agitation and containment borne by hospitals 
and the health care system.
Mental HealtH – Patient-reported outcomes & Patient Preference studies
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objeCtives: Nowadays selective serotonin reuptake inhibitors (SSRIs) are the most 
frequently prescribed antidepressants due to their better clinical efficacy, effec-
tiveness, tolerability, and safety, when compared to tricyclic antidepressants or 
monoamino oxidase inhibitors. However, despite this, especially at the beginning 
of treatment SSRIs are associated with side effects, which may lead to premature 
discontinuation of therapy in some cases. Assessment of these factors was the aim 
of the present study. Methods: This retrospective database analysis used data 
from 50,824 patients first time treated with SSRIs for major depressive disorder 
selected from a Electronic Medical Records (EMR) database (IMS Disease Analyzer) 
in Germany, providing information on SSRI side effects and their influence on pre-
mature treatment discontinuation calculated by regression analysis. In addition to 
that, presence of certain co-morbidities was registered. Results: Mean age was 
54.5 ± 19 years with two-thirds of study population being female. Most frequently 
mentioned adverse effects were “discomfort” of the digestive system (10%), sleep 
disorders (8.6%), and heart rhythm disorders (4%); however, these were of tolerable 
severity as they did not significantly influence dropout rate. Contrary to that, espe-
cially somnolence and younger age (≤ 50 years) increased the chance of premature 
treatment discontinuation, while patients suffering from cardiovascular risk factors 
or osteoporosis tended to adhere to therapy. ConClusions: Overall, the findings 
indicate a good tolerability of SSRIs at the beginning of treatment, whereas occur-
rence of somnolence leads to incompliance.
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objeCtives: The aim of this study to explore patients’ general and specific beliefs 
about medicines among depressed patients and effect on adherence Methods: 
A cross-sectional design used to measure patients’ general and specific beliefs 
among depressed patients, using BMQ general and specific scale. Patients were 
recruit from outpatient clinic at AL-Amal hospital in Riyadh (psychiatric hospital) 
between 2013 and January 2014. Results: A total of 403 patients meet the inclu-
sion criteria and were participated in this study. Two hundred three representing 
50.37 % of the total study sample, were female, while the remaining 200 (49.6 %) 
were male, with average 39 years. Half of the patients (52.9%) report low adherence 
to antidepressant medication. Both low and high adherence group scored high in 
the necessity beliefs (18.02 (SD 3.91) -18.32 (SD 3.9) respectively with no statistically 
different. contrariwise patients with high adherence had significantly lower level of 
concerns belief about antidepressants medication and less harmful belief also the 
same finding with general overuse belief. ConClusions: General patients beliefs 
either general overuse or general harm about medication influence patients taking 
medication behavior and have negative correlation with adherence to medication 
on another hand only specific concerns belief to antidepressant have a positive 
correlation with adherence to antidepressant this finding will help psychiatric to 
improve adherence and clinical outcome by addressing medications taking behavior 
using a systematic approach based in this finding.
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objeCtives: Patients adherence studies are essential for evaluating the quality of 
care delivery of a health facility and patients’ role in improving their conditions. 
The objective of this study is to determine the level of adherence of outpatients to 
psychotropic drugs and evaluate the impacting factors. Methods: The study was 
a cross-sectional study done at the psychiatric hospital, Uselu, Benin city, Nigeria 
from April to September, 2013. Convenient sampling method was used in popula-
tion size determination for data collection. The participants were adult patients (18 
years and above) attending the outpatients psychiatric clinic of the hospital with 
diagnosis of various psychiatric illnesses. A total of 250 patients participated in the 
study and a well-structured self-report 10-item questionnaire using the medica-
tion adherence rating scale (MARS) was used. Additional information was patients’ 
socio-demographic profile and clinical variables that affect patients’ adherence to 
medications. Adherence to medication data were analyzed with respect to gender 
and level of adherence and factors that impact patients’ adherence. Results: The 
level of patients’ adherence to psychotropic was 63.6% and factors found to signifi-
cantly affect adherence include amount spent per clinic visit, perception of social 
support, intake of alcohol, medication side effects, and existing denial of illness and 
use of traditional medicine. ConClusions: The level of adherence to psychotropic 
medications was fairly high and factors that were significantly related to adherent 
status were amount spent per clinic visit, perception of social support, intake of 
alcohol, medication side effects, existing denial of illness and use of traditional 
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objeCtives: The purpose of the present study is to conduct an economic evaluation 
of Agomelatine vs the current alternatives in daily clinical practice for treating patients 
with major depression disorders (MDD) in Italy (Venlafaxine, Fluoxetine, Sertraline, 
Escitalopram and Duloxetine). Methods: Using a Markov model-based cost-effec-
tiveness analysis, Agomelatine was compared with other therapies used for the treat-
ment of MDD commonly prescribed (Venlafaxine, Fluoxetine, Sertraline, Escitalopram 
and Duloxetine), chosen on the basis of market shares, and compared with placebo. 
The population considered in the model consists of patients suffering from MDD 
and with an average age of 45 years. The perspective of the third party payer (Italian 
National Healthcare Service) and the societal perspective were considered. Results: 
The study shows that Agomelatine administration is linked with higher direct and 
indirect costs only when compared with Duloxetine (respectively € 4,365 vs. € 4,253 
and € 5,553 vs. € 5,484). Nevertheless, Agomelatine has the higher efficacy in terms 
of QALY gained (1.477) in comparison to all comparators considered in the analysis. 
According to the societal perspective, Agomelatine is dominant against Venlafaxine, 
Escitalopram, Fluoxetine and Sertraline, since it is less expensive and more effective 
and cost-effective compared to Duloxetine since the incremental cost per QALY gained 
is € 12,461. According to the perspective of the Italian NHS, Agomelatine is dominant 
versus Venlafaxine, Fluoxetine and Sertraline and is cost-effective in comparison to 
Duloxetine (ICER 6,101 € /QALY) and Escitalopram (3,336 € /QALY). ConClusions: 
The present economic evaluation indicates that Agomelatine provides greater ben-
efit and is less costly compared to generic Venlafaxine, generic Escitalopram, generic 
Fluoxetine and generic Sertraline and that Agomelatine is cost-effective compared to 
Duloxetine. In conclusion, according to its favorable tolerability profile and its proven 
efficacy, Agomelatine represents a powerful tool for many patients suffering from 
MDD, which may lead to both clinical and economic advantages.
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objeCtives: The Swedish national payer, TLV, was interested in understanding how 
OLAI is used in routine clinical practice regarding dosing and its impact on psychiat-
ric-related hospitalization. Methods: Three Swedish nationwide health registers: 
the patient register, the drug register and the mortality register were linked. Patients 
with ≥ 1 prescription of OLAI and one diagnosis of schizophrenia or schizoaffective 
disorder prior to initiation of OLAI were included in this retrospective patient mirror-
image study. The minimum follow-up was six months. The study period was from 
03/2010 until 12/2011. The average number and duration of hospitalizations were 
compared before and after initiation with OLAI using a Student’s t-test. Results: 
70 patients met the inclusion criteria. The proportion of patients being hospitalized 
≥ 1 was 77% in the pre-index period and 67% in the post-index period. The number of 
outpatient visits increased from 45% prior to OLAI to 77% post initiation. The results 
showed a significant reduction in the mean length of stay per hospitalization (19.6 
days vs 3.9 days [p< 0.001] ), and in the mean total number of days spent in hospital 
per patient (52.3 days vs. 16.2 days [p< 0.001] ). No significant difference was seen in 
the number of hospital visits between the pre- and post-initiation periods, although 
there was a numerical decrease observed within the post-index period. The average 
dose of OLAI was 18.1 mg per day (95% CI: 16.6 mg; 19.7 mg) and the prescription 
refill period was 19.6 days (95% CI: 17.7 days; 21.5 days). ConClusions: This study 
provides evidence that initiation with OLAI significantly reduces the length of stay 
per hospitalization and the total days spent in hospital.
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objeCtives: The aim of this study was to evaluate the use of services and costs 
related to agitation and containment of adult patients admitted to a psychiatric 
hospital. Methods: Systematic review through searches of Pubmed, CINHAL and 
Web of Knowledge (using a wide variety of terms related to agitation; inpatient care 
and use of services/costs); bibliographic references in retrieved studies and expert 
consultation. Studies published since 1998 were selected in duplicate by review-
ing abstracts and full-text papers. Results: After removing duplicates, 372 papers 
were reviewed and 11 included in the review. Four studies were of high quality, 4 
of moderate-high to moderate-low quality and three of low quality. Eight of the 
studies evaluated the impact of agitation on the length of stay and 6 showed that 
it was associated with longer stays. Four studies evaluated the impact of agitation 
on readmission and showed a statistically significant increase in the probability of 
readmission of agitated patients in comparison with non-agitated patients. Two 
studies evaluated medication, one showed that the mean medication dose was 
higher in agitated patients and the other found higher costs of treatment com-
pared with non-agitated patients in the unadjusted analysis. Another estimated 
the costs of conflict and containment related to acute inpatient psychiatric care 
in UK. The total annual cost in England for all conflict was £72.55 million (£145,177 
annual conflict cost per ward) and £106 million for containment (£212,316 annual 
containment cost per ward). ConClusions: Studies on use of services and costs 
of agitation are scarce. Overall, agitation has an effect on health care use and costs 
